{
  "id": "urinary-tract-infection",
  "title": "Urinary tract infection",
  "lang": "en",
  "source_lang": "en",
  "summary": "An infection of the urinary system, usually bacterial, ranging from bladder infection to kidney infection and systemic illness.",
  "category": "health",
  "subcategory": "diseases",
  "type": "concept",
  "aliases": [
    "UTI",
    "urinary infection",
    "urinary tract infections"
  ],
  "generated_at": "2026-10-13",
  "model": "pro/gpt-6.1-sol",
  "url": "https://aiwiki.page/en/urinary-tract-infection/",
  "translations": {
    "zh-Hans": {
      "url": "https://aiwiki.page/zh/urinary-tract-infection/",
      "json": "https://aiwiki.page/zh/urinary-tract-infection.json"
    }
  },
  "sections": [
    {
      "heading": "",
      "text": "A urinary tract infection (UTI) is an infectious disease affecting part of the urinary system, which includes the kidneys, ureters, bladder, and urethra. Most UTIs are caused by bacteria, particularly Escherichia coli. Bladder infection, or cystitis, is the most common form; infection involving the kidneys is called pyelonephritis. Clinical severity ranges from localized urinary symptoms to systemic illness and, in some cases, sepsis. (niddk.nih.gov)\n\nUTIs occur across the lifespan but are especially common in women. Their importance reflects their frequency, tendency to recur, contribution to healthcare-associated infection, and substantial use of antibiotics. Diagnosis distinguishes symptomatic infection from asymptomatic bacteriuria—the presence of bacteria in urine without attributable symptoms—which generally has different clinical implications. The subject encompasses microbial causes and host defenses, clinical classification, diagnostic testing, population-specific features, treatment and prevention, and the effects of antibiotic resistance on healthcare practice. (niddk.nih.gov)"
    },
    {
      "heading": "Anatomical scope and clinical classification",
      "text": "A urinary tract infection is an infectious disease affecting part of the urinary tract: the urethra, bladder, ureters, or kidneys. Anatomically, the bladder and urethra constitute the lower tract, while the ureters and kidneys constitute the upper tract. Bladder infection, usually caused by bacteria entering and multiplying in the bladder, is termed infectious cystitis. However, cystitis denotes bladder inflammation, not necessarily infection; interstitial cystitis, also called bladder pain syndrome, is a distinct condition whose diagnosis requires exclusion of urinary infection and other causes of similar symptoms. Thus, neither bladder pain nor the word “cystitis” alone establishes an infectious cause. (niddk.nih.gov)\n\nLower-tract infection is commonly represented clinically by cystitis, whereas pyelonephritis is infection of one or both kidneys. Kidney infection often develops when organisms ascend from the bladder through the ureters, although anatomical classification describes the affected site rather than proving the route of spread. The lower–upper distinction therefore separates bladder disease from renal involvement; it is not interchangeable with the uncomplicated–complicated distinction. In particular, older guidelines recognized “uncomplicated pyelonephritis” in selected patients, despite its upper-tract location. (niddk.nih.gov)\n\nTraditional classifications generally restricted uncomplicated UTI to otherwise healthy, nonpregnant women without relevant structural or functional urinary abnormalities, and classified infections outside that population as complicated. The IDSA/ESCMID 2010 guideline update, published in March 2011 and authored by Kalpana Gupta and colleagues, was specifically limited to premenopausal, nonpregnant women without known urological abnormalities or comorbidities. Other systems used broader or different eligibility criteria. Consequently, “complicated” could refer to host characteristics, urinary obstruction, instrumentation, or an infection’s clinical extent, rather than consistently indicating severe illness. A study’s inclusion criteria must therefore be distinguished from the classification used in another guideline; the same label does not necessarily identify comparable patient populations. (idsociety.org)\n\nIn 2025, the European Association of Urology (EAU) introduced a localized–systemic framework in place of uncomplicated–complicated terminology. Localized UTI means cystitis without systemic signs or symptoms in either sex. Systemic UTI means urinary infection accompanied by systemic manifestations, with or without local urinary symptoms; examples include pyelonephritis, acute prostatitis, and urinary-source sepsis. Relevant manifestations include fever or hypothermia, shaking chills, tachycardia, hypotension, and costovertebral-angle pain or tenderness, although these findings can have nonurinary causes. Risk factors are recorded separately: obstruction, urinary stones, residual urine, catheters, pregnancy, impaired immunity, and resistant organisms can accompany either localized or systemic infection. Systemic infection is therefore not synonymous with sepsis, and localized infection does not imply absence of treatment-related risks. (uroweb.org)\n\nThe Infectious Diseases Society of America (IDSA) retained uncomplicated–complicated terminology in its guideline published on July 17, 2025, but changed its treatment-oriented meaning. Infection apparently confined to the bladder can be uncomplicated in women or men; fever, other systemic illness, or clinical evidence of extension beyond the bladder supports classification as complicated. Diabetes, immunocompromise, or a urological abnormality no longer automatically makes an otherwise bladder-confined infection complicated. Symptomatic infection associated with long-term urinary catheters, stents, or nephrostomy tubes is nevertheless classified as complicated because the device affects management. Unlike the EAU framework, which permits catheter-associated infection to be localized or systemic, IDSA therefore retains a device-related category within complicated UTI. Its classification is explicitly intended to guide treatment, not establish the diagnosis; infection extent, underlying risk factors, and acute severity remain distinct considerations. (idsociety.org)"
    },
    {
      "heading": "Epidemiology and disease burden",
      "text": "Bladder infection is substantially more common in women than in men. In its adult bladder-infection information reviewed in April 2024, the US National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) estimates that approximately half of all women develop a bladder infection during their lifetime, and about one quarter of those affected have repeat infections. The population is women, and the endpoint is at least one lifetime bladder infection—not annual incidence, the proportion currently infected, or specifically kidney infection. NIDDK also states that bladder infections are uncommon in men younger than 50. The female predominance is partly explained by a shorter urethra close to intestinal bacterial reservoirs; sexual activity and menopause are associated with increased susceptibility. Incomplete bladder emptying and prostatic enlargement help explain infection risk in older men. (niddk.nih.gov)\n\nHealthcare-use data illustrate a different dimension of frequency. An analysis of the US National Ambulatory Medical Care Survey for 2016, 2018, and 2019 estimated approximately 9.80 million UTI-related physician-office encounters annually among people aged 15 years and older, with a 95% confidence interval of 8.68–10.91 million. Women accounted for 71.0% of weighted encounters, while adults aged 65 and older accounted for 55.6%. These are distributions of recorded visits, not age-specific population infection rates. Cases were identified through diagnostic codes rather than systematic microbiological confirmation. The analysis separately estimated approximately 3.95 million affected patients annually, demonstrating why encounters cannot be equated with individuals: one person may attend repeatedly for the same illness or experience several infections. (cambridge.org)\n\nCommunity-acquired disease must also be distinguished from infection acquired during healthcare. A community-onset infection may require hospital admission without having originated in the hospital. Conversely, urinary devices create a distinct exposure in hospitals and long-term care. CDC reports that 15–25% of hospitalized patients receive urinary catheters and that approximately 75% of UTIs developing in hospitals are catheter-associated. These percentages concern hospital populations, not all UTIs in the community. Catheter-associated infections contribute additional morbidity, longer hospital stays, and healthcare expenditure; prolonged catheter use is their most important risk factor. (cdc.gov)\n\nLong-term-care estimates require particular care because bacterial detection is not equivalent to symptomatic infection. The Infectious Diseases Society of America’s 2019 guideline reports prevalence ranges for asymptomatic bacteriuria of 25–50% among older women and 15–50% among older men residing in long-term-care facilities. These figures describe bacteria in urine without attributable infection symptoms, not the prevalence of symptomatic UTI. (idsociety.org) Catheter-associated colonization further complicates counting: CDC estimates that bacteriuria develops in 3–7% of catheterized patients per day and is present in nearly all after one month. Counting positive cultures alone would therefore substantially overstate the symptomatic disease burden in these populations. (cdc.gov)\n\nDisease burden includes expenditure, repeated treatment, and disruption of daily activities as well as infection counts. CDC’s clinical overview cites pre-pandemic estimates of approximately 2.7 million emergency-department visits annually and 400,000 annual hospitalizations with UTI as the principal diagnosis, the latter associated with approximately US$2.8 billion in healthcare costs. These historical estimates are not contemporaneous national totals and should not simply be added to office-visit counts. Recurrent infections generate further consultations and antibiotic exposure and can impair quality of life. (cdc.gov) Unnecessary treatment of catheter-associated asymptomatic bacteriuria adds a separate, avoidable burden, including adverse drug events, Clostridioides difficile infection, and selection of antibiotic resistance. (cdc.gov)"
    },
    {
      "heading": "Causative microorganisms",
      "text": "Bacteria cause most urinary tract infections, with Escherichia coli the predominant organism. Uropathogenic E. coli (UPEC) belongs to the broader group of extraintestinal pathogenic E. coli, which can cause disease outside the intestine. Its urinary pathogenicity is distinct from the mechanisms defining diarrheal pathotypes, such as Shiga toxin-producing and enterotoxigenic E. coli. Thus, identifying E. coli in a urinary infection does not imply infection with a diarrheal strain or a preceding episode of gastroenteritis. Most E. coli normally inhabit the intestine without causing disease; the species name alone does not specify its pathogenic behavior. (cdc.gov)\n\nThe intestinal population is an important reservoir of urinary pathogens, rather than a completely separate population of harmless organisms. In a year-long study published in 2022, Colin J. Worby and colleagues followed 15 women with recurrent infections and 16 controls, using stool, urine, and blood samples. Genomic analyses connected urinary E. coli strains with strains carried in the gut, and infection-associated strains could remain in the intestine despite antibiotic exposure. Related strains also appeared in the bladders of controls without producing symptoms. These observations distinguish carriage of a potentially uropathogenic organism from symptomatic disease: the organism’s properties, its location, and the host’s response all matter. (nature.com)\n\nOther bacterial causes include Klebsiella pneumoniae, Proteus mirabilis, and Enterobacter species, including the Enterobacter cloacae complex. Their relative importance varies with the clinical setting. In US National Healthcare Safety Network data for 2018–2021, E. coli accounted for 33.5% of reported adult catheter-associated urinary infection pathogens in hospital intensive care units, compared with 14.5% for the selected Klebsiella group and 4.5% for Enterobacter. These percentages describe reported pathogens in a surveillance population, not the distribution of all community urinary infections. Pseudomonas aeruginosa and enterococci also contributed to this healthcare-associated spectrum. P. mirabilis is particularly associated with long-term urinary catheterization and abnormal urinary tracts. Its urease breaks down urea, raises urinary pH, and promotes mineral precipitation; experimental studies have demonstrated bacteria embedded within urease-induced urinary stones. (cdc.gov)\n\nStaphylococcus saprophyticus is especially associated with community-acquired infection in young women. Its clinical importance is illustrated by a 1983 study by R. H. Latham, K. Running, and W. E. Stamm: during 14 months of observation among college women, it caused 11% of urinary infections and was the second most frequent organism after E. coli. The investigators evaluated 81 S. saprophyticus infections in 72 women and found that symptoms and urinalysis findings resembled those of E. coli infection. That proportion pertains to the studied population and period, rather than constituting a universal estimate for all ages or healthcare settings. (pubmed.ncbi.nlm.nih.gov)\n\nFungal urinary infection is less common than bacterial infection; Candida yeasts can cause cystitis or kidney infection. However, candiduria—the detection of Candida in urine—is not equivalent to symptomatic candidiasis. The Infectious Diseases Society of America’s 2016 guideline states that candiduria in an asymptomatic person almost always represents colonization. It is particularly associated with urinary devices, antibiotic exposure, older age, and diabetes. Even inflammatory cells or a high yeast colony count may fail to distinguish colonization from infection in catheterized patients. Symptomatic ascending infection and kidney involvement during bloodstream candidiasis are distinct clinical situations; a positive urine culture alone establishes neither. (niddk.nih.gov)"
    },
    {
      "heading": "Routes of infection and microbial pathogenesis",
      "text": "The usual route of infection is ascending: bacteria from the intestinal reservoir colonize the perineal and periurethral region, enter the urethra, and reach the bladder, where they multiply. Genetic comparisons of rectal and urinary Escherichia coli isolates support this fecal–perineal–urethral pathway. Organisms can subsequently ascend through the ureters to one or both kidneys. Less commonly, microorganisms reach the kidneys through the bloodstream from an infection elsewhere in the body; this hematogenous route differs from the bladder-first sequence characteristic of most kidney infections. (pubmed.ncbi.nlm.nih.gov)\n\nAttachment to the urothelium, the epithelial lining of the urinary tract, helps bacteria remain associated with tissue despite urinary flow. Uropathogenic E. coli (UPEC) commonly produces type 1 pili, also called fimbriae: hair-like surface fibers with a shaft principally composed of FimA subunits and a distal tip carrying the adhesin FimH. FimH recognizes mannose-containing host glycoproteins; experimental binding studies identified uroplakin Ia, a protein of the bladder’s superficial epithelial cells, as one receptor. Thus, adhesion depends on specific molecular recognition rather than nonspecific contact with the bladder surface. The pilus also has mechanical properties relevant to attachment under flow. Johan Zakrisson and colleagues’ 2013 numerical model predicted that uncoiling of the type 1 pilus shaft reduces force transmitted to the adhesin–receptor bond during changing flow, while permitting FimH to adopt a stronger-binding state. This was a biomechanical model, not a measurement of attachment forces in patients. (journals.asm.org)\n\nAdhesion can also initiate epithelial entry. In a 2000 study, Juan J. Martinez, Matthew A. Mulvey, and colleagues showed that FimH promoted UPEC internalization in cultured human bladder epithelial cells. Uptake required localized reorganization of the host actin cytoskeleton, activation of phosphoinositide 3-kinase, and protein tyrosine phosphorylation. In these experimental systems, the host membrane envelops attached bacteria through a “zippering” process. Mouse infection experiments further established that internalized UPEC can multiply within superficial bladder cells, forming dense, biofilm-like aggregates termed intracellular bacterial communities (IBCs). In the murine pathway, communities disperse, bacteria leave infected cells—sometimes with an elongated, filamentous morphology—and some establish quiescent intracellular reservoirs capable of seeding subsequent infection. This experimental sequence should not be assumed to occur in every human episode. (pubmed.ncbi.nlm.nih.gov)\n\nCell-culture models reproduce particular features of intracellular growth, but not necessarily the complete mouse pathway. In 2009, Ruth E. Berry, David J. Klumpp, and Anthony J. Schaeffer studied UPEC in immortalized human urothelial cells using fluorescence microscopy and a gentamicin protection assay to assess intracellular bacteria. Pretreatment of host cells with the cholesterol-binding agent filipin increased intracellular bacterial numbers at 8 and 24 hours after infection. Dense IBC-like aggregates developed within LAMP1-positive vacuoles, distinguishing these structures from the cytoplasmic communities described in mice. The pharmacologically manipulated culture system demonstrated a capacity for intracellular proliferation; it did not establish how frequently such structures form in an intact human bladder. (pubmed.ncbi.nlm.nih.gov)\n\nDirect clinical observations provide narrower evidence. In a study published on December 18, 2007, David A. Rosen and colleagues examined urine from 80 young, otherwise healthy women with acute uncomplicated cystitis and 20 asymptomatic women with a history of UTI. Microscopy detected exfoliated epithelial cells containing IBCs in 14 of the 80 symptomatic samples (18%) and filamentous bacteria in 33 (41%); neither finding appeared in the comparison group. These observations support intracellular bacterial growth in some human bladder infections. Because the study examined shed cells in urine rather than following bacteria longitudinally within bladder tissue, it did not establish the full intracellular life cycle, the duration of reservoirs, or their contribution to later recurrence in individual patients. (pmc.ncbi.nlm.nih.gov)"
    },
    {
      "heading": "Host defenses and predisposing conditions",
      "text": "Urinary flow provides a mechanical defense by carrying bacteria out of the urinary tract during bladder emptying. This flushing limits the opportunity for organisms entering through the urethra to remain and multiply. Conversely, residual urine after voiding reduces clearance and provides a reservoir in which bacteria can proliferate. Chronic urinary retention may occur even when a person can still urinate, so the passage of urine does not necessarily indicate complete emptying. (niddk.nih.gov)\n\nThe urothelium—the epithelial lining of the urinary collecting system—also functions as a physical barrier and an active component of innate immunity. Closely joined epithelial cells restrict access to underlying tissues, while antimicrobial peptides and locally produced signaling molecules help control microbial invasion. In a 2006 study, Milan Chromek and colleagues demonstrated production of the antimicrobial peptide cathelicidin in human and mouse urinary epithelia; bacterial contact triggered rapid peptide release. Experiments in cathelicidin-deficient mice supported a protective role, although these experimental findings do not establish how much individual human susceptibility depends on this pathway. Local immune responses also recruit neutrophils: human studies found that urinary interleukin-8, a neutrophil-attracting chemokine, increased during infection and correlated with urinary neutrophil numbers. (pubmed.ncbi.nlm.nih.gov)\n\nFemale urethral anatomy favors bacterial access: the urethra is shorter than the male urethra, and its opening lies close to the anus, an important source of intestinal bacteria. Sexual activity and spermicide-containing contraception are additional associations, but ordinary bacterial cystitis is not classified as a sexually transmitted infection. (niddk.nih.gov) In a 2000 case-control study, Delia Scholes and colleagues compared 229 women aged 18–30 with recurrent infections against 253 controls. Spermicide use during the preceding year was independently associated with recurrence, with an odds ratio of 1.8 and a 95% confidence interval of 1.1–2.9; intercourse frequency and a new sexual partner were also associated. These estimates concern recurrent infection in the studied population, rather than the probability that any individual sexual encounter causes infection. (pubmed.ncbi.nlm.nih.gov)\n\nChanges accompanying menopause affect the genital environment adjacent to the urethra. Reduced estrogen is associated with mucosal atrophy, higher vaginal pH, and diminished lactobacillus colonization, conditions that can favor colonization by intestinal organisms. Evidence connecting these features comes from studies of postmenopausal women with recurrent infection, rather than all postmenopausal women. In a 1993 trial by Raul Raz and Walter Stamm, vaginal estriol lowered mean vaginal pH from 5.5 to 3.8, and lactobacilli reappeared after one month in 22 of 36 assessed estriol recipients but in none of 24 placebo recipients. These findings illustrate a hormone-sensitive local defense mechanism; preventive treatment is addressed separately. (nejm.org)\n\nObstruction and impaired bladder function undermine mechanical clearance. Benign prostatic hyperplasia can compress the urethra, while urinary stones may obstruct drainage. Weak bladder contraction or disrupted nerve control can likewise leave residual urine, including after spinal cord injury or diabetic nerve damage. (niddk.nih.gov) Vesicoureteral reflux is a different disturbance: urine flows backward from the bladder into one or both ureters and sometimes reaches the kidneys. Often related to inadequate closure at the ureter–bladder junction, it is particularly relevant in children and is associated with urinary infection, although it does not itself demonstrate that infection is present. (niddk.nih.gov)\n\nDiabetes mellitus and impaired immune function are recognized predisposing conditions for both bladder and kidney infection. Diabetes may combine metabolic disturbances with impaired bladder emptying, rather than acting through one universal mechanism. Immune impairment may arise from disease or treatment; chemotherapy is one example identified in clinical information on UTI risk. These conditions can coexist with anatomical or drainage abnormalities, so susceptibility reflects overlapping defects in clearance and host defense rather than a single risk factor. (niddk.nih.gov)"
    },
    {
      "heading": "Symptoms and clinical signs",
      "text": "Bladder infection typically produces a recent onset of dysuria—pain, burning, or stinging during urination—together with urinary frequency and urgency. Frequency means urinating more often than usual; urgency is a compelling need to urinate that is difficult to defer. Suprapubic discomfort occurs in the lower abdomen over the bladder and may be described as pressure, aching, or cramping. New urinary leakage can accompany these symptoms. In localized cystitis, the clinical picture is predominantly urinary: fever, shaking chills, flank pain, and marked general illness are not characteristic of infection confined to the bladder. (niddk.nih.gov)\n\nHematuria, or blood in the urine, may accompany bladder infection, but it is neither necessary for the diagnosis nor specific to infection. Visible blood can make urine pink, red, or brown; microscopic hematuria does not visibly change its color. Infection or inflammation involving the bladder, urethra, kidneys, or prostate can cause urinary bleeding, but stones and other urinary disorders can do so as well. Thus, the presence of blood describes a clinical finding rather than establishing its cause. Cloudy or strong-smelling urine may also occur during bladder infection, although these changes have substantially less diagnostic meaning when isolated from urinary symptoms. (niddk.nih.gov)\n\nKidney infection, or pyelonephritis, commonly produces fever, chills, and pain in the back or flank, sometimes extending toward the groin, together with nausea or vomiting. Examination may reveal costovertebral-angle tenderness, near the junction of the lower ribs and spine. Dysuria, frequency, and urgency may coexist, but systemic urinary infection can also occur without prominent bladder symptoms. Consequently, the absence of burning urination does not exclude upper-tract illness. The combination of urinary symptoms with fever, chills, flank pain, or a generally unwell appearance differs clinically from the predominantly local discomfort of cystitis. (niddk.nih.gov)\n\nMore extensive illness may include rapid heart rate, low blood pressure, altered mental status, or an abnormally low temperature rather than fever. Kidney infection can occasionally be associated with sepsis, whose manifestations may include confusion, rapid breathing, shortness of breath, and severe discomfort. These findings indicate systemic illness but do not independently identify the urinary tract as its source. Likewise, urine odor, cloudiness, or discoloration alone does not establish symptomatic infection: CDC urine-culture stewardship guidance specifically identifies these isolated changes, without other localizing signs or symptoms, as insufficient grounds for urine culturing. (uroweb.org)\n\nPresentation varies with age and the ability to perceive or communicate symptoms. Children younger than two years with kidney infection may have high fever without recognizable urinary complaints, sometimes accompanied by feeding difficulty or poor weight gain. In older adults with cognitive impairment, symptom reporting may be difficult, but confusion or a fall alone—even when bacteria are detected in urine—does not establish a symptomatic UTI. The Infectious Diseases Society of America’s 2019 guideline distinguishes these nonspecific events from presentations containing local urinary symptoms or systemic findings such as fever or circulatory instability. (niddk.nih.gov)"
    },
    {
      "heading": "Urine testing and diagnostic interpretation",
      "text": "Clinical history and examination establish the context in which urine results are interpreted. Dysuria, frequency, and urgency support a bladder source, whereas fever and flank tenderness raise concern for upper-tract involvement. Previous infections, recent antibiotic exposure, pregnancy, and urinary devices affect the choice and interpretation of tests. Urinalysis provides evidence of urinary inflammation or bacterial activity; culture identifies organisms that grow under laboratory conditions. Neither replaces clinical assessment: bacteria in urine without attributable symptoms may represent asymptomatic bacteriuria rather than symptomatic infection. (niddk.nih.gov)\n\nDipstick testing detects leukocyte esterase, an enzyme associated with white blood cells, and nitrite, produced when certain bacteria reduce urinary nitrate. Leukocyte esterase supports the presence of pyuria, or increased urinary white blood cells, but does not identify its cause. Nitrite positivity supports bacteriuria, particularly with nitrate-reducing organisms such as Escherichia coli. A negative nitrite result does not exclude infection: some organisms do not produce nitrite, and frequent voiding may leave insufficient bladder residence time for detectable amounts to accumulate. Microscopy can quantify white cells and show bacteria, red cells, and epithelial cells. Pyuria indicates inflammation, not necessarily bacterial infection; it may accompany asymptomatic bacteriuria or occur despite a negative routine culture, a finding termed sterile pyuria. (auanet.org)\n\nSpecimen collection determines how confidently growth can be attributed to the urinary tract. A clean-catch midstream specimen collects urine after voiding has begun, limiting carryover of periurethral organisms, although contamination remains possible. Catheter-obtained specimens bypass voided collection; with an indwelling catheter, fresh urine is collected aseptically through the sampling port rather than from the drainage bag. Suprapubic aspiration obtains bladder urine directly through the abdominal wall. NICE’s 2022 pediatric guideline favors clean-catch collection where possible and uses catheterization or suprapubic aspiration when non-invasive collection is impractical, with ultrasound confirmation of bladder urine before aspiration. Mixed growth may reflect contamination or delayed processing, although genuine mixed infection occurs; epithelial cells alone do not reliably establish contamination. (gov.uk)\n\nPreservation prevents changes in bacterial numbers between collection and analysis. Organisms can multiply in urine left at room temperature, producing misleadingly high colony counts. NICE specifies immediate refrigeration or boric-acid preservation when a pediatric specimen cannot be cultured within four hours. Preservative containers require the specified urine volume: underfilling can create an excessively concentrated boric-acid solution that inhibits bacteria and produces false-negative culture results. Boric acid can also interfere with leukocyte-esterase testing, so preserved culture specimens are not interchangeable with fresh specimens for dipstick analysis. Collection before antibiotic exposure improves interpretability, because treatment can suppress bacterial growth. (nice.org.uk)\n\nUrine culture reports organism identity and growth quantity, usually expressed as colony-forming units per milliliter (CFU/mL). Susceptibility testing assesses the recovered organism’s response to antimicrobial agents and can inform treatment selection; results typically take several days. Colony counts are not governed by a universal diagnostic threshold. Although many laboratories use \\(10^{4}\\)–\\(10^{5}\\) CFU/mL to support diagnosis, a single isolate at \\(10^{2}\\) CFU/mL can be significant in strongly symptomatic women, and a pure or predominant organism at \\(10^{3}\\) CFU/mL can be significant in symptomatic men. Specimen type also matters: IDSA’s 2019 guideline notes that counts from \\(10^{2}\\) to below \\(10^{5}\\) CFU/mL after intermittent catheterization or insertion of a new catheter can represent true bacteriuria, while their significance in people without symptoms remains uncertain. Counts therefore require interpretation alongside symptoms, inflammatory findings, collection method, and patient population, rather than classification as infection solely because growth exceeds a numerical cutoff. (niddk.nih.gov)"
    },
    {
      "heading": "Differential diagnosis and additional investigations",
      "text": "Urethritis and vaginal infection can produce dysuria without bacterial infection of the bladder. Urethral itching or mucoid or purulent discharge suggests urethral inflammation; Neisseria gonorrhoeae and Chlamydia trachomatis are important infectious causes. The CDC’s 2021 sexually transmitted infection guidelines identify nucleic acid amplification tests as the preferred tests for these organisms, using specimens appropriate to the anatomical site. These tests answer a different diagnostic question from routine bacterial urine culture. Vaginal discharge, itching, soreness, or vulvar redness shifts the differential toward vaginitis. For example, vulvovaginal candidiasis can cause external dysuria, in which urination is associated with pain at inflamed external genital tissue. Examination and testing of vaginal secretions, including microscopy or culture where indicated, distinguish vaginal disease from urinary infection more reliably than symptoms alone. (cdc.gov)\n\nInterstitial cystitis/bladder pain syndrome is characterized by bladder-related pain, pressure, or discomfort accompanied by lower urinary tract symptoms lasting more than six weeks, without infection or another identifiable cause. Pain that increases with bladder filling and improves after voiding is characteristic, although presentations vary. Persistent symptoms with repeatedly negative cultures therefore require consideration of this syndrome rather than automatic attribution to recurrent bacterial cystitis. Urinary stones are another overlapping diagnosis: they may cause painful urination, urgency, hematuria, and sharp flank, abdominal, or groin pain that comes in waves. Stones can also coexist with infection, so identifying a calculus does not by itself exclude UTI. (pmc.ncbi.nlm.nih.gov)\n\nHematuria also raises the possibility of urinary tract malignancy, especially when it persists after an apparent infection has resolved. The American Urological Association and Society of Urodynamics, Female Pelvic Medicine and Urogenital Reconstruction’s 2025 microhematuria guideline specifies repeat microscopic urinalysis after treatment when blood in the urine has been attributed to UTI. Subsequent investigation is risk-stratified, incorporating factors such as age, smoking history, the degree of hematuria, and previous visible bleeding. Intermediate-risk evaluation includes renal ultrasonography and cystoscopy, whereas high-risk evaluation includes cystoscopy and axial imaging of the upper urinary tract, usually CT urography when suitable. These are investigations of unexplained bleeding and possible malignancy, not routine tests for cystitis. (auanet.org)\n\nBlood tests principally assess systemic illness and renal function rather than establish ordinary localized bladder infection. Their role becomes greater when fever or other systemic manifestations suggest kidney infection or more extensive disease. Blood cultures serve a separate purpose: detecting bloodstream infection and identifying its organism. European Association of Urology guidance identifies sepsis or severe illness as indications for blood cultures; it also highlights Staphylococcus aureus isolated from urine because this finding can accompany bloodstream infection. Blood testing thus supplements, rather than replaces, clinical assessment and urine investigations. (niddk.nih.gov)\n\nImaging is selective. In systemic UTI, Ultrasonography can identify urinary retention or hydronephrosis; computed tomography or other cross-sectional imaging investigates suspected upper-tract obstruction, abscess, severe illness, or symptoms persisting despite 48–72 hours of appropriate antimicrobial treatment. For recurrent localized infection, extensive routine imaging and cystoscopy have low diagnostic yield, but atypical features suggesting stones, outflow obstruction, or cancer justify further investigation. Cystoscopy passes an instrument through the urethra to inspect the urethral and bladder interior directly, complementing imaging when a structural or mucosal abnormality is suspected. (uroweb.org)"
    },
    {
      "heading": "Asymptomatic bacteriuria",
      "text": "Asymptomatic bacteriuria (ASB) is the presence of bacteria in urine at specified quantitative counts without signs or symptoms attributable to urinary infection. It can occur with or without pyuria, the presence of white blood cells in urine; pyuria therefore does not, by itself, distinguish ASB from symptomatic infection. For voided specimens from people without indwelling catheters, the 2019 Infectious Diseases Society of America (IDSA) guideline defines ASB using a count of \\(\\geq 10^{5}\\) colony-forming units per milliliter. In women, two consecutive specimens, preferably within two weeks, establish persistence; in men, one qualifying specimen is sufficient. These are criteria for asymptomatic bacteriuria, not a universal threshold for diagnosing symptomatic UTI. (idsociety.org)\n\nA positive culture establishes bacterial growth, but does not establish that eliminating those bacteria will improve health. Antibiotic treatment can clear bacteriuria temporarily without preventing subsequent symptomatic infection. In a randomized controlled trial published in 2002, Godfrey K. M. Harding, Lindsay E. Nicolle, and colleagues assigned 105 women with diabetes and ASB to antimicrobial treatment or placebo. Four weeks after the initial treatment course, bacteriuria remained in 20% of treated women and 78% of placebo recipients. Nevertheless, over a mean follow-up of 27 months, at least one symptomatic UTI occurred in 42% of treated women and 40% of placebo recipients. The study thus demonstrated a substantial microbiological effect without a corresponding reduction in symptomatic illness. (nejm.org)\n\nUnnecessary antibiotic exposure introduces adverse drug effects, Clostridioides difficile infection, and selection for antibiotic resistance. Routine cultures in asymptomatic people can promote overdiagnosis when bacterial growth is interpreted as an automatic indication for treatment. IDSA’s 2019 guidance discourages screening and treatment in groups including healthy nonpregnant women, older adults, people with diabetes, and people with spinal cord injury. These populations may carry bacteria without a treatment-responsive urinary illness. The U.S. Preventive Services Task Force likewise recommends against screening asymptomatic nonpregnant adults, although its recommendation excludes hospitalized or institutionalized people and those with chronic medical or urinary conditions. (idsociety.org)\n\nPregnancy is an established exception because treating screen-detected ASB reduces the risk of pyelonephritis. The American College of Obstetricians and Gynecologists’ August 2023 consensus supports one urine culture early in prenatal care and culture-directed treatment of significant ASB. It also emphasizes limitations in the evidence: much of the supporting research dates from the 1960s and 1970s, and two more recent trials reported pyelonephritis rates of only 2.2–2.4% among untreated participants. The lower contemporary baseline risk affects estimates of absolute benefit but has not displaced the screening recommendation. Evidence remains insufficient to determine the value of repeat screening after a negative initial culture or after treatment. (acog.org)\n\nThe other principal exception is an endoscopic urologic procedure that causes mucosal trauma: bacteriuria in this setting increases the risk of postoperative sepsis. IDSA supports preprocedural culture and targeted, brief perioperative antimicrobial treatment, rather than prolonged eradication therapy. This exception does not extend to elective nonurologic surgery. Separate evidence gaps identified in the 2019 guideline include ASB during the first month after kidney transplantation, high-risk neutropenia following chemotherapy, and screening or treatment specifically at urinary-catheter removal. These are unresolved questions, not established additional indications for treating all positive cultures. (idsociety.org)"
    },
    {
      "heading": "Infection during pregnancy",
      "text": "During pregnancy, progesterone reduces ureteral smooth-muscle tone, promoting dilation and slower urine transport. Compression by the enlarging uterus further impairs drainage; urinary stasis makes bacterial clearance less effective and facilitates ascending infection. These changes increase susceptibility without making infection inevitable. (pmc.ncbi.nlm.nih.gov) The American College of Obstetricians and Gynecologists (ACOG), in its August 2023 clinical consensus, estimates that urinary tract infections affect approximately 8% of pregnancies. This estimate encompasses the obstetric spectrum of bacteriuria and symptomatic infection, rather than kidney infection alone. Urinary infection is associated with preterm delivery and low birth weight; these associations do not establish infection as the cause of every adverse outcome. (acog.org)\n\nObstetric practice distinguishes asymptomatic bacteriuria, in which significant bacterial growth occurs without attributable urinary symptoms, from acute cystitis, which produces symptoms such as dysuria, urgency, or hematuria. Frequency and nocturia also occur normally during pregnancy, so their presence alone is insufficient to identify infection. Pyelonephritis involves the kidney: ACOG’s diagnostic framework includes fever of at least \\(38.0\\,^\\circ\\mathrm{C}\\), urine findings suggesting infection, and supporting features such as flank pain or costovertebral-angle tenderness. (acog.org)\n\nPregnancy is an established exception to the general avoidance of antibiotic treatment for asymptomatic bacteriuria. The Infectious Diseases Society of America’s 2019 guideline supports urine-culture screening early in pregnancy and treatment when significant bacteriuria is identified. For voided specimens, its quantitative definition uses at least \\(10^{5}\\) colony-forming units per milliliter, irrespective of pyuria. Historical trials reported that treatment reduced pyelonephritis among pregnant participants with bacteriuria from approximately 20–35% to 1–4%. Much of this evidence dates from the 1960s–1980s, and contemporary populations may have lower untreated risks. Evidence is insufficient to establish the benefit of repeated screening after a negative initial culture or after treatment. (idsociety.org)\n\nFor symptomatic lower-tract infection, culture identifies the organism and its antimicrobial susceptibility. NICE’s guideline describes obtaining a midstream specimen before antibiotics, beginning treatment without waiting for the result, and subsequently adjusting the drug to the susceptibility findings. Its pregnancy regimens generally last seven days. Examples include nitrofurantoin and cefalexin; amoxicillin is reserved for culture-confirmed susceptible organisms. Selection also depends on renal function, previous antibiotic exposure, and pregnancy-specific safety restrictions. NICE excludes nitrofurantoin at term because of possible neonatal hemolysis, illustrating why suitability earlier in pregnancy does not imply suitability throughout gestation. (nice.org.uk)\n\nPyelonephritis carries maternal risks including sepsis, disseminated intravascular coagulation, and acute respiratory distress syndrome. ACOG describes initial inpatient management with parenteral antibiotics, followed by culture-directed adjustment and oral treatment after clinical improvement, completing 14 days in total. Adequate drug penetration into renal tissue is essential: nitrofurantoin and fosfomycin can be useful for lower-tract infection but do not achieve therapeutic concentrations in the renal parenchyma and are unsuitable for completing pyelonephritis treatment. (acog.org)"
    },
    {
      "heading": "Infection in infants and children",
      "text": "Infants often lack the recognizable urinary symptoms of older children. In children younger than 2 years, infection may present as unexplained fever, irritability, poor feeding, poor weight gain, vomiting, or diarrhea. Older, verbal children more often describe painful urination, urgency, frequency, or lower abdominal pain; new wetting after toilet training is another possible manifestation. Fever with flank or back pain and vomiting suggests upper-tract involvement, although anatomical localization from symptoms is difficult in infancy. These differences make pediatric diagnosis dependent on age, clinical findings, and appropriately collected urine rather than on adult symptom-based pathways. (niddk.nih.gov)\n\nSpecimen collection is particularly important before toilet training. Clean-catch urine can be obtained from some infants, whereas toilet-trained children generally provide a midstream specimen. Catheterization or suprapubic aspiration provides samples suitable for culture when noninvasive collection is impractical; the Canadian Paediatric Society favors catheter specimens for culture in incontinent children. Adhesive collection bags can supply urine for screening urinalysis, but their contamination risk makes positive bag cultures unsuitable for confirming infection. Collection ordinarily precedes antibiotic exposure because even one dose can suppress bacterial growth. The Society’s 2026 statement uses specimen-dependent examples of significant growth: at least \\(5\\times10^{4}\\) colony-forming units/mL for catheter urine, at least \\(10^{5}\\)/mL for clean-catch or midstream urine, and any growth of a recognized uropathogen from suprapubic aspiration. Symptoms, urinalysis, and organism identity remain essential to interpretation; mixed growth usually indicates contamination. (cps.ca)\n\nDipstick interpretation follows age-specific pathways. NICE guideline NG224, published in 2022, places suspected infection in infants younger than 3 months within specialist assessment, with urgent microscopy and culture rather than dipstick-only exclusion. Between 3 months and 3 years, positivity for either leukocyte esterase or nitrite generally leads to culture; two negative results usually exclude infection unless clinical circumstances warrant further investigation. From age 3 years, isolated leukocyte esterase positivity requires culture and clinical correlation rather than automatically establishing infection. Culture also has a role when symptoms contradict dipstick findings or upper-tract infection is suspected. (nice.org.uk)\n\nChildhood recurrence is not defined by the adult six- or twelve-month thresholds. NICE defines recurrent infection as two or more upper-tract episodes, one upper-tract episode plus at least one lower-tract episode, or three or more lower-tract episodes. Its “atypical” category includes serious illness, poor urinary flow, an abdominal or bladder mass, raised creatinine, septicemia, non-E. coli infection, or failure to respond to appropriate treatment within 48 hours. These features identify children requiring investigation beyond an ordinary first infection. (nice.org.uk)\n\nImaging is selective and differs among guidelines. NICE specifies ultrasonography within six weeks for infants younger than 6 months after a first infection responding to treatment; the Canadian Paediatric Society supports ultrasound after a first infection in children younger than 24 months. Ultrasound can identify obstruction and congenital urinary abnormalities. NICE uses delayed dimercaptosuccinic acid (DMSA) scintigraphy, usually four to six months after infection, in selected atypical or recurrent cases to assess renal parenchymal defects, while reserving reflux imaging for specified circumstances rather than every infection. (cps.ca)\n\nVesicoureteral reflux permits urine to move backward from the bladder toward the ureters and sometimes the kidneys. Primary reflux reflects an abnormal ureter–bladder junction present from birth; secondary reflux can accompany obstruction or impaired bladder function. Repeated infection, high-grade reflux, and delayed treatment are associated with increased renal-scarring risk, but most children with reflux do not develop lasting problems. Renal abnormalities also may precede infection: severe congenital reflux can interfere with kidney development. Consequently, later renal damage requires interpretation alongside developmental abnormalities, reflux severity, and documented infection history, rather than attribution to every childhood bladder infection. (niddk.nih.gov)"
    },
    {
      "heading": "Infection in men, older adults, and medically vulnerable populations",
      "text": "In men, urinary infection requires attention to both the bladder and the prostate. Benign prostatic hyperplasia can cause bladder-outlet obstruction and leave substantial residual urine after voiding; prostatic infection may also accompany urinary symptoms or contribute to recurrent episodes. These factors affect evaluation and antimicrobial selection rather than establishing severity by themselves. NICE’s lower-UTI guideline calls for a midstream urine culture before antibiotic treatment in men and notes that nitrofurantoin is unsuitable when prostate involvement is suspected because it does not reliably achieve therapeutic concentrations in prostatic tissue. The European Association of Urology’s localized–systemic classification does not treat male sex alone as a risk factor: bladder-confined infection can occur in either sex, while prostatic involvement, obstruction, impaired emptying, and systemic manifestations are assessed separately. (nice.org.uk)\n\nOlder adults frequently have bacteria in urine without symptomatic infection. The 2019 Infectious Diseases Society of America (IDSA) guideline summarized reported prevalences of asymptomatic bacteriuria of 10.8–16% in community-dwelling women aged at least 70 years and 3.6–19% in men of that age; corresponding ranges in long-term-care facilities were 25–50% and 15–50%. These figures describe bacteriuria without attributable symptoms, not the prevalence of symptomatic UTI. Consequently, a positive culture—even with pyuria—has limited diagnostic specificity in these populations. Cognitive or communication impairment may complicate symptom assessment, but neither bacteriuria nor urinary leukocytes independently establish the cause of a new illness. (idsociety.org)\n\nDelirium and falls are particularly important sources of diagnostic misattribution. Observational associations between delirium and bacteriuria do not establish that urinary bacteria caused the mental-status change; age, comorbidity, and reduced mobility can confound the association. IDSA’s 2019 guideline distinguishes bacteriuria accompanied only by delirium or a fall from infection supported by local urinary symptoms or systemic signs such as fever and hemodynamic instability. In the former situation, its recommendations favor assessment for other causes and observation rather than antimicrobial treatment of bacteriuria. This distinction does not exclude urinary infection in a patient with sepsis and no identified source, whose evaluation must encompass both urinary and nonurinary infection. (idsociety.org)\n\nSpinal cord injury and neurogenic bladder alter both urinary emptying and the symptoms available for diagnosis. Impaired sensation may remove dysuria or bladder pain from the presentation, while bacteriuria is common with intermittent catheterization. Possible manifestations include newly increased spasticity, new or worsening incontinence, leakage around a catheter, malaise, fever, or autonomic dysreflexia. Their significance depends on a recent change from baseline, accompanying bacteriuria and pyuria, and the absence of another explanation; chronically cloudy or malodorous urine alone is insufficient. IDSA discourages routine screening and treatment of asymptomatic bacteriuria after spinal cord injury, distinguishing persistent colonization from episodes accompanied by compatible clinical changes. (academic.oup.com)\n\nAfter organ transplantation, diagnostic interpretation also depends on the transplanted organ and time since surgery. Kidney recipients have additional risks from urinary reconstruction and ureteral stents; symptomatic infection may present principally with fever, malaise, leukocytosis, or a nonspecific sepsis syndrome rather than localized urinary complaints. Nevertheless, transplantation does not make every positive culture an infection. IDSA’s 2019 guideline recommends against screening or treating asymptomatic bacteriuria more than one month after kidney transplantation, while identifying insufficient evidence for the first month; it also recommends against such screening and treatment in nonrenal solid-organ recipients. Evidence from otherwise healthy adults cannot simply be transferred to these groups: trials supporting some 2025 IDSA treatment recommendations largely excluded immunocompromised patients, severe renal impairment, and structural or functional urinary abnormalities. (pubmed.ncbi.nlm.nih.gov)"
    },
    {
      "heading": "Catheter-associated and healthcare-associated infection",
      "text": "Urinary catheters provide routes for microbial entry and surfaces for persistent colonization. Organisms from the patient’s periurethral, intestinal, or vaginal flora, or from contaminated hands and equipment, can ascend along the catheter’s outer surface. They can also enter its lumen through a contaminated drainage bag or catheter–tubing junction. With prolonged catheterization, microorganisms form a biofilm on catheter and drainage-system surfaces, which protects them against antimicrobial activity and host defenses. Catheter-associated infection accounts for a substantial share of healthcare-associated urinary disease: the US Centers for Disease Control and Prevention (CDC) estimates that approximately 75% of UTIs acquired in hospitals are associated with a urinary catheter. (cdc.gov)\n\nDuration of catheterization strongly affects colonization. CDC estimates that bacteriuria develops at a rate of approximately 3–7% per catheter day and is present in nearly all patients after one month of continuous catheterization; these figures describe bacteria in urine, not symptomatic infection. Catheter-associated asymptomatic bacteriuria lacks attributable symptoms and generally does not require antibiotic treatment, apart from established exceptions such as pregnancy and selected invasive urological procedures. Clinical catheter-associated UTI requires compatible manifestations and microbiological evidence, with no other identified source explaining the illness. Pyuria alone does not distinguish infection from colonization. Unnecessary treatment exposes patients to adverse drug effects and selection of resistant organisms without establishing clinical benefit. (cdc.gov)\n\nSpecimen collection must avoid contamination from accumulated drainage-bag urine. For urinalysis or culture, CDC specifies aseptic collection of fresh urine through the catheter’s disinfected sampling port using sterile equipment, rather than collection from the bag. Clinical interpretation and surveillance classification serve different purposes. For example, the CDC’s clinical culture-stewardship guidance describes a threshold of \\(10^3\\) colony-forming units per millilitre in a symptomatic catheterized patient, whereas the January 2026 National Healthcare Safety Network (NHSN) symptomatic-UTI criterion requires a culture containing no more than two organism species, including at least one bacterium at \\(10^5\\) colony-forming units per millilitre or more. These thresholds are not interchangeable universal diagnostic rules. (cdc.gov)\n\nNHSN catheter association additionally requires an indwelling urethral catheter to have been present for more than two consecutive inpatient calendar days, counting insertion as day 1, and to be present on the event date or the preceding day. Thus, an otherwise qualifying event after removal remains catheter-associated only if its event date is the removal day or the next day. External urine-collection devices, intermittent catheters, and suprapubic catheters do not meet this particular device definition. The symptomatic surveillance criterion includes fever, suprapubic tenderness, or costovertebral-angle pain or tenderness; urgency, frequency, and dysuria cannot be counted while an indwelling catheter remains in place because the device itself can cause them. (cdc.gov)\n\nInstitutional prevention begins with limiting insertion to appropriate indications, including acute urinary retention, accurate urine-output measurement in critically ill patients, and selected operations—not routine incontinence management. CDC’s 2009 prevention guideline specifies trained personnel, hand hygiene, aseptic insertion with sterile equipment, closed drainage, and unobstructed flow. Tubing is kept free of kinks and the bag below bladder level and off the floor. Daily necessity review, reminders, and nurse-directed removal protocols reduce unnecessary catheter exposure; postoperative removal is preferably within 24 hours unless continued use is indicated. Routine fixed-interval replacement and routine preventive systemic antibiotics are not recommended. Facilities monitor infections per 1,000 catheter-days and catheter utilization, alongside adherence to insertion, maintenance, and removal practices. (cdc.gov)"
    },
    {
      "heading": "Treatment of localized bladder infection",
      "text": "Oral antibiotics are used to eradicate susceptible bacteria in symptomatic bladder infection. Common examples include nitrofurantoin, trimethoprim alone or combined with sulfamethoxazole, and oral fosfomycin. Their place in treatment differs among guidelines and populations. NICE’s 2018 lower-UTI guideline lists nitrofurantoin and trimethoprim, when resistance risk is low, as first choices for nonpregnant adult women, with fosfomycin among alternatives. The IDSA–ESCMID 2010 update, published in 2011, described these agents for a narrower population: premenopausal, nonpregnant women without known urological abnormalities or important comorbidities. Bladder-directed treatment is not interchangeable with treatment of kidney infection: nitrofurantoin and oral fosfomycin lack adequate renal-tissue concentrations for suspected pyelonephritis. (nice.org.uk)\n\nInitial drug selection may be empirical, but it incorporates local antibiotic resistance patterns, previous urine cultures, recent antibiotic exposure, allergy history, and renal function. Culture and susceptibility results can subsequently identify an inactive drug or support a narrower-spectrum alternative. Recent trimethoprim use, particularly within the preceding three months, increases concern about resistance. Renal function is especially relevant to nitrofurantoin: NICE generally restricts its use to an estimated glomerular filtration rate of at least \\(45\\ \\mathrm{mL/minute}\\), while allowing selected cautious use at lower values for resistant lower-tract infection. These thresholds are guideline-specific rather than universal prescribing rules. Suspected prostatic involvement also changes selection because nitrofurantoin does not reliably reach therapeutic concentrations in the prostate. (nice.org.uk)\n\nTreatment duration depends on the agent, population, and supporting evidence, rather than on urinary symptoms alone. NICE describes three-day nitrofurantoin or trimethoprim courses for nonpregnant adult women and seven-day courses for men and pregnant women; fosfomycin is listed as a single-dose option for nonpregnant women. The earlier IDSA–ESCMID guideline instead described five-day nitrofurantoin and three-day trimethoprim–sulfamethoxazole regimens in its defined population. Pregnancy introduces additional drug-safety restrictions, including avoidance of nitrofurantoin at term because of possible neonatal haemolysis. Evidence from otherwise healthy adult women therefore cannot automatically determine treatment duration or drug suitability in pregnancy, childhood, or suspected prostate disease. (nice.org.uk)\n\nClinical resolution and microbiological eradication are separate outcomes: disappearance of dysuria, frequency, and discomfort is not identical to elimination of the organism from a follow-up culture. In a 2018 multinational, open-label randomized controlled trial, Angela Huttner and colleagues enrolled 513 nonpregnant adult women with uncomplicated lower UTI. Clinical resolution through 28 days after treatment occurred in 70% of evaluable nitrofurantoin recipients and 58% of fosfomycin recipients; microbiological resolution was 74% and 63%, respectively. The comparison involved five-day nitrofurantoin and single-dose fosfomycin, so its findings concern those regimens and the trial population, not every possible use of either drug. (pubmed.ncbi.nlm.nih.gov)\n\nSymptom-relieving treatment serves a different purpose from bacterial eradication. Analgesics can reduce pain, but do not establish that infection has cleared; NICE’s evidence review found greater symptom burden and more subsequent antibiotic use with an ibuprofen-first strategy than with antibiotic treatment. Antibiotic adverse effects include nausea and diarrhoea. Nitrofurantoin additionally has recognized pulmonary and hepatic risks: an April 2023 UK regulatory reminder noted that pulmonary reactions can occur during short courses, including the first treatment week, and that hepatic injury can occur with treatment of any duration. Symptoms that worsen or fail to begin improving within approximately 48 hours prompt clinical reassessment, including culture review and consideration of resistant bacteria, upper-tract infection, prostatic involvement, or an alternative diagnosis, rather than automatic repetition of bladder-directed therapy. (nice.org.uk)"
    },
    {
      "heading": "Treatment of pyelonephritis and systemic infection",
      "text": "Treatment of pyelonephritis requires an antibiotic that is active against the infecting organism and reaches therapeutic concentrations in kidney tissue; high concentrations in urine alone do not establish suitability. When infection is accompanied by bacteremia, adequate exposure in the bloodstream is also necessary. Nitrofurantoin and oral fosfomycin, although used for bladder infection, are generally unsuitable for pyelonephritis because their renal-tissue exposure is inadequate. This distinction concerns the site of infection and the drug’s distribution, rather than simply whether a laboratory reports the organism as susceptible. (nice.org.uk)\n\nEmpiric treatment begins before organism identification and susceptibility results are available. The Infectious Diseases Society of America’s 2025 guideline organizes selection around illness severity, especially the presence of sepsis; previous resistant urinary isolates and antibiotic exposure; patient-specific contraindications and interactions; and, in septic patients, a relevant local antibiogram. Examples of initial agents include third- or fourth-generation cephalosporins and piperacillin–tazobactam, with carbapenems among the options for septic patients when the assessment supports their use. Broader coverage is not automatically preferable in nonseptic disease. Once urine-culture identification and susceptibility results become available, definitive treatment uses an effective agent with a targeted spectrum rather than continuing broad empiric coverage throughout the course. (idsociety.org)\n\nIntravenous administration is used when severe illness, vomiting, or inability to take oral medication makes oral treatment unsuitable; selected patients can receive oral therapy from the outset. NICE describes reassessment of intravenous treatment by 48 hours, whereas the 2025 IDSA transition recommendation emphasizes clinical improvement, ability to take oral medication, and availability of an effective oral agent. Efficacy depends on adequate drug exposure, not on intravenous administration itself. In studies supporting oral transition for Gram-negative bacteremia, patients were generally afebrile and hemodynamically stable, and urinary obstruction had been relieved before the switch. Oral transition also reduces exposure to intravenous-device complications. Supporting trials commonly excluded patients with indwelling urinary catheters, severe renal insufficiency, immunocompromised states, or major urinary-tract abnormalities, limiting direct extrapolation to these groups. (nice.org.uk)\n\nAntibiotics do not replace control of an obstructed or drainable infectious focus. Source control includes decompression of urinary obstruction, drainage of clinically significant urinary-tract abscesses, and removal of implicated foreign bodies where appropriate. In urosepsis, these interventions accompany prompt antimicrobial treatment and supportive management of organ dysfunction. Persistent symptoms or inadequate improvement after 48–72 hours of appropriate therapy can prompt further imaging to identify obstruction, renal or perinephric abscess, or another complication requiring intervention. Simply extending the same antibiotic course does not address such an anatomical source. (uroweb.org)\n\nFor patients improving on effective therapy, the 2025 IDSA guideline supports shorter courses: 5–7 days for a fluoroquinolone, or 7 days for a non-fluoroquinolone, rather than routinely using 10–14 days. It also supports 7 rather than 14 days for clinically improving patients with associated Gram-negative bacteremia. Duration is counted from the first day of effective treatment. Evidence certainty is moderate for short fluoroquinolone courses but very low for non-fluoroquinolone courses; evidence for short oral beta-lactam regimens is particularly limited. Most supporting studies excluded patients with severe sepsis, urinary abscesses, complete obstruction, indwelling catheters, immunocompromising conditions, chronic kidney disease, bacterial prostatitis, or urologic surgery. These exclusions leave the optimal duration less established in those populations; suspected prostatic involvement may also require a longer course than otherwise eligible upper-tract infection. (idsociety.org)"
    },
    {
      "heading": "Recurrence and preventive interventions",
      "text": "Recurrent UTI in adults is commonly defined as at least two symptomatic episodes within six months or three within twelve months. Recurrence may represent relapse, involving the same microbial strain, or reinfection, involving a different strain or species. This distinction concerns microbial identity rather than symptom frequency alone. Most preventive evidence concerns recurrent bladder infection in adult women, not repeated kidney infection, catheter-associated infection, or infection in people with major urinary abnormalities; the European Association of Urology emphasizes urine-culture confirmation of recurrent cystitis. (nice.org.uk)\n\nVaginal estrogen has population-specific evidence in women after menopause. Its proposed protective mechanism includes restoration of vaginal lactobacilli, reduced vaginal pH, and decreased colonization by intestinal bacteria capable of entering the urinary tract. In a 1993 placebo-controlled trial, Raul Raz and Walter Stamm studied 93 postmenopausal women: intravaginal estriol was associated with 0.5 UTIs per patient-year, compared with 5.9 with placebo. Lactobacilli reappeared after one month in 61% of evaluated estriol recipients and none of the placebo recipients. These findings concern local vaginal treatment, not systemic hormone therapy; NICE distinguishes vaginal estrogen from systemic hormone replacement prescribed specifically for UTI prevention. (nejm.org)\n\nAntibiotic prophylaxis has been studied as either continuous low-dose treatment or a single dose associated with an identifiable trigger, particularly sexual intercourse. Trials and meta-analyses show reduced recurrence during prophylaxis, without a significant efficacy difference between continuous and postcoital approaches. Studied continuous courses generally lasted three to twelve months; an optimal duration is not established, and infections commonly recur after discontinuation. Drug selection reflects previous cultures, susceptibility patterns, and prior antibiotic exposure. Adverse effects and selection for antibiotic resistance limit the benefit of prolonged exposure; prophylaxis is distinct from treating an established symptomatic episode. (uroweb.org)\n\nMethenamine hippurate provides a non-antibiotic prophylactic alternative. In the 2022 open-label ALTAR randomized controlled trial, 240 women were allocated to methenamine or daily low-dose antibiotics for twelve months. Symptomatic, antibiotic-treated UTIs occurred at rates of 1.38 and 0.89 episodes per person-year, respectively. The difference met the trial’s prespecified non-inferiority criterion, although the numerical infection rate was higher with methenamine. NICE’s December 2024 update incorporated it as an alternative for selected nonpregnant people with a female urinary system. Supporting evidence was confined to nonpregnant adult women, limiting extrapolation to men, children, pregnancy, and complicated or recurrent upper-tract infection. Urine-alkalinizing products can reduce its effectiveness, and it is not treatment for acute UTI. (bmj.com)\n\nEvidence for cranberry products varies by population and formulation. A 2023 Cochrane review found a probable reduction in symptomatic, culture-confirmed UTI among women with recurrent infection: eight studies involving 1,555 participants yielded a risk ratio of 0.74, with a 95% confidence interval of 0.55–0.99. Benefits were not established in institutionalized older adults, pregnant women, or adults with neuromuscular bladder dysfunction; optimal preparation and dose remain uncertain. Hydration has more narrowly defined trial evidence: Thomas Hooton and colleagues’ 2018 study enrolled 140 premenopausal women drinking less than 1.5 litres of fluid daily. Adding 1.5 litres of water daily reduced mean cystitis episodes over twelve months from 3.2 to 1.7. Probiotic studies differ in bacterial strain, oral or vaginal administration, and treatment duration, leaving insufficient evidence for a standardized regimen. (cochrane.org)\n\nEarly studies suggested benefit from D-mannose, but a larger placebo-controlled trial did not demonstrate efficacy in its primary-care population. Published in 2024 by Gail Hayward and colleagues, the double-blind study randomized 598 women from 99 UK primary-care centres to daily D-mannose or placebo for six months. A medically attended, clinically suspected UTI occurred in 51.0% of participants with outcome data in the D-mannose group and 55.7% in the placebo group. The risk difference was approximately −5 percentage points, with a 95% confidence interval of −13 to 3 percentage points; neither the primary outcome nor secondary outcomes showed a statistically significant benefit. The endpoint was a clinically suspected infection prompting healthcare contact, rather than exclusively culture-confirmed infection. (jamanetwork.com)"
    },
    {
      "heading": "Complications and prognosis",
      "text": "Most bladder infections diagnosed early and treated appropriately resolve without complications. An untreated infection can ascend through the ureters to one or both kidneys, producing pyelonephritis, but this is a possible progression rather than an inevitable outcome of cystitis. Most promptly treated kidney infections also have a favorable prognosis; uncommon outcomes include renal scarring, hypertension, and kidney failure. Prognosis is less favorable when infection occurs alongside urinary obstruction, structural abnormalities, impaired immunity, or pre-existing kidney disease. Recurrent bladder infection and recurrent kidney infection are therefore not equivalent indicators of future renal damage. (niddk.nih.gov)\n\nIn upper-tract infection, bacteria may enter the bloodstream, producing bacteremia. This describes the presence of bacteria in blood and is distinct from sepsis, which the 2016 Sepsis-3 consensus defined as life-threatening organ dysfunction caused by a dysregulated response to infection. Sepsis originating in the urinary tract is termed urosepsis. Widespread inflammation, vascular leakage, and disturbed circulation can impair oxygen delivery to organs; septic shock involves particularly severe circulatory and metabolic abnormalities. Kidney dysfunction during such an episode may consequently reflect systemic illness as well as local renal infection. Obstructive pyelonephritis is especially important because infection behind a blocked urinary drainage pathway can progress rapidly to urosepsis. (niddk.nih.gov)\n\nLocalized suppuration can produce a renal abscess, a collection of pus within kidney tissue, or a perinephric abscess, situated outside the renal capsule. A renal abscess can extend into the surrounding tissues; some abscesses instead arise through bloodstream spread from another site. Diabetes mellitus and urinary stones are prominent associated conditions in clinical series. Persistent fever or failure to improve during treatment can indicate an abscess or unresolved obstruction: European Association of Urology guidance identifies these complications as reasons for additional imaging when symptoms persist after 48–72 hours of appropriate therapy. Such infections may require drainage in addition to antimicrobial treatment, rather than simply a longer course for presumed uncomplicated pyelonephritis. (pmc.ncbi.nlm.nih.gov)\n\nAn uncommon, destructive form of upper-tract infection is emphysematous pyelonephritis, in which gas-forming organisms cause necrosis and gas accumulation in renal tissue or surrounding spaces. Its prognosis differs substantially from that of ordinary cystitis. A multicenter study published in 2022 examined 570 affected patients treated at 22 centers in 11 countries between 2013 and 2020: 70.0% had diabetes, and overall mortality was 12.1%. Escherichia coli was the most frequently isolated organism. These figures describe a selected population with an already severe complication, not the probability that an ordinary urinary infection will become fatal. (pmc.ncbi.nlm.nih.gov)\n\nRenal scarring and later chronic kidney disease require interpretation in relation to congenital abnormalities, reflux, recurrent upper-tract infection, and the extent of renal damage. In a 2024 Welsh population-based study, Kathryn Hughes and colleagues followed 159,201 children, including 11,099 with microbiologically confirmed UTI before age five. Diagnosed renal scarring by age seven occurred in 1.24% of children with UTI, compared with 0.08% without UTI. After adjustment for underlying risk factors, the study found no statistically significant association with hypertension, chronic kidney disease, or end-stage renal failure over approximately ten years of follow-up. Most children were not systematically scanned, and the findings do not establish lifetime risk. NICE guidance likewise distinguishes minor unilateral renal defects from bilateral abnormalities, impaired function, hypertension, or proteinuria, which carry different follow-up implications. These distinctions prevent renal impairment from being attributed indiscriminately to every episode of recurrent bladder infection. (pmc.ncbi.nlm.nih.gov)"
    },
    {
      "heading": "Antimicrobial resistance and research development",
      "text": "Antimicrobial resistance limits both initial treatment and subsequent culture-directed therapy. Extended-spectrum beta-lactamases (ESBLs), found in uropathogens including Escherichia coli and Klebsiella pneumoniae, inactivate many penicillins and cephalosporins. ESBL production does not itself confer resistance to unrelated drug classes, but ESBL-producing organisms frequently carry additional resistance determinants. Consequently, the resistance mechanism and the isolate’s measured susceptibility both matter. The IDSA’s 2026 guidance identifies several potentially active agents for ESBL-associated bladder infection, including nitrofurantoin and trimethoprim–sulfamethoxazole; their inclusion does not imply that every ESBL-producing isolate is susceptible. Carbapenem resistance further restricts options and makes identification of the underlying mechanism important. (idsociety.org)\n\nLocal susceptibility patterns help estimate whether an empiric antibiotic will cover the likely pathogen before individual culture results become available. An antibiogram summarizes susceptibility among organisms collected in a defined setting; it is not a substitute for the patient’s own results. The 2025 IDSA complicated-UTI guideline defines a useful antibiogram as local to the healthcare facility, based on the preceding 12 months, and relevant to a similar patient population. For urinary-source sepsis, its suggested susceptibility thresholds are at least 80% without shock and 90% with septic shock, derived from mortality-risk modelling. Previous resistant urinary isolates and recent antibiotic exposure also inform selection. (idsociety.org)\n\nAntimicrobial stewardship begins with diagnostic decisions. The 2019 IDSA guideline identifies unnecessary urine cultures as a driver of inappropriate treatment: a positive result can prompt antibiotics even when symptoms attributable to urinary infection are absent. Avoiding routine screening and treatment of asymptomatic bacteriuria, except in established circumstances such as pregnancy and selected endourologic procedures involving mucosal trauma, reduces avoidable exposure. (idsociety.org) Once symptomatic infection is established, stewardship includes narrowing empiric coverage to a culture-directed agent and limiting treatment to an effective duration. The 2025 guideline supports shorter courses in clinically improving patients, while noting that supporting studies often excluded catheterized patients and those with severe sepsis, abscesses, or substantial immunocompromise. (idsociety.org)\n\nExperimental research has also examined persistence mechanisms distinct from inherited antibiotic resistance. In 2009, Ruth E. Berry, David J. Klumpp, and Anthony J. Schaeffer developed a culture model of uropathogenic E. coli proliferation within immortalized human urothelial cells, extending earlier observations of intracellular bacterial communities in mice. Gentamicin-protection assays and fluorescence microscopy helped distinguish intracellular organisms from extracellular bacteria and characterize biofilm-like aggregates. Such systems permit investigation of bacterial survival inside host cells, but findings in mice or cultured cells do not establish that intracellular communities cause every human recurrence or justify prolonged antimicrobial treatment on their own. (pubmed.ncbi.nlm.nih.gov)\n\nModern prevention research illustrates the importance of testing antibiotic-sparing approaches in clinical populations rather than relying solely on plausible mechanisms. Chris Harding and colleagues’ 2022 ALTAR randomized trial assigned 240 adult women to methenamine hippurate or daily antibiotic prophylaxis. Symptomatic, antibiotic-treated infections occurred at 1.38 versus 0.89 episodes per person-year; the difference met the prespecified non-inferiority margin of one episode per person-year, rather than demonstrating identical efficacy. (bmj.com) By contrast, Gail Hayward and colleagues’ 2024 placebo-controlled trial enrolled 598 women from UK primary care. Over six months, medically attended, clinically suspected UTI occurred in 51.0% of the D-mannose group and 55.7% of the placebo group, without a statistically significant difference. (jamanetwork.com)\n\nRevised classifications have changed how treatment evidence is organized. The IDSA guideline released on July 17, 2025, emphasizes infection confined to the bladder versus infection extending beyond it, rather than treating male sex alone as sufficient to define complicated infection. This treatment-oriented framework separates anatomical extent from resistance risk and individual contraindications. It accompanies a decision process based on illness severity, prior microbiology, patient-specific factors, and relevant local susceptibility data, rather than designation of a single preferred empiric drug for all complicated infections. (idsociety.org)"
    }
  ],
  "links": [
    "infectious-disease",
    "bacteria",
    "escherichia-coli",
    "kidney",
    "sepsis",
    "antibiotic-resistance",
    "inflammation",
    "fever",
    "kidney-stones",
    "pregnancy",
    "diabetes-mellitus",
    "diagnosis",
    "incidence",
    "menopause",
    "prevalence",
    "quality-of-life",
    "fungi",
    "innate-immunity",
    "neutrophil",
    "benign-prostatic-hyperplasia",
    "nausea",
    "blood-test",
    "ultrasonography",
    "x-ray-computed-tomography",
    "randomized-controlled-trial",
    "surgery",
    "abdominal-pain",
    "organ-transplantation",
    "public-health-surveillance",
    "pain",
    "chronic-kidney-disease",
    "primary-health-care"
  ],
  "sources": [
    {
      "title": "Definition & Facts of Bladder Infection in Adults - NIDDK",
      "url": "https://www.niddk.nih.gov/health-information/urologic-diseases/bladder-infection-uti-in-adults/definition-facts"
    },
    {
      "title": "Definition & Facts of Kidney Infection (Pyelonephritis) - NIDDK",
      "url": "https://www.niddk.nih.gov/health-information/urologic-diseases/kidney-infection-pyelonephritis/definition-facts"
    },
    {
      "title": "Diagnosis of Interstitial Cystitis - NIDDK",
      "url": "https://www.niddk.nih.gov/health-information/urologic-diseases/interstitial-cystitis-bladder-pain-syndrome/diagnosis"
    },
    {
      "title": "IDSA 2010 Clinical Practice Guideline Update for the Treatment of Acute Uncomplicated Cystitis and Pyelonephritis in Women",
      "url": "https://www.idsociety.org/practice-guideline/uncomplicated-cystitis-and-pyelonephritis-uti/"
    },
    {
      "title": "EAU Guidelines on Urological Infections - THE GUIDELINE",
      "url": "https://uroweb.org/guidelines/urological-infections/chapter/the-guideline?s=04"
    },
    {
      "title": "New classification of UTIs: From uncomplicated/complicated to localised/systemic UTIs - Uroweb",
      "url": "https://uroweb.org/news/new-classification-of-utis-from-uncomplicated-complicated-to-localised-systemic-utis"
    },
    {
      "title": "IDSA 2025 Guideline Update on Complicated Urinary Tract Infections",
      "url": "https://www.idsociety.org/practice-guideline/complicated-urinary-tract-infections"
    },
    {
      "title": "Complicated urinary tract infections: New guidelines Q&A",
      "url": "https://www.idsociety.org/science-speaks-blog/2025/complicated-urinary-tract-infections-new-guidelines-qa/"
    },
    {
      "title": "Assessing the burden of outpatient urinary tract infections in the United States: analysis of nationwide ambulatory data (2016–2019)",
      "url": "https://www.cambridge.org/core/services/aop-cambridge-core/content/view/DA4144246F6890872549E0BD73C6FB5F/S2732494X25100454a.pdf/assessing-the-burden-of-outpatient-urinary-tract-infections-in-the-united-states-analysis-of-nationwide-ambulatory-data-2016-2019.pdf"
    },
    {
      "title": "Clinical Safety: Preventing Catheter-associated Urinary Tract Infections (CAUTIs)",
      "url": "https://www.cdc.gov/uti/hcp/clinical-safety/index.html"
    },
    {
      "title": "Clinical Practice Guideline for the Management of Asymptomatic Bacteriuria: 2019 Update",
      "url": "https://www.idsociety.org/globalassets/idsa/practice-guidelines/2019-asymptomatic-bacteriuria.pdf"
    },
    {
      "title": "Indwelling Urinary Catheter Culture Stewardship: Overview",
      "url": "https://www.cdc.gov/uti/hcp/clinical-guidance/"
    },
    {
      "title": "Clinical Overview of Urinary Tract Infections",
      "url": "https://www.cdc.gov/uti/hcp/clinical-overview/"
    },
    {
      "title": "Kinds of E. coli",
      "url": "https://www.cdc.gov/ecoli/about/kinds-of-ecoli.html"
    },
    {
      "title": "Longitudinal multi-omics analyses link gut microbiome dysbiosis with recurrent urinary tract infections in women",
      "url": "https://www.nature.com/articles/s41564-022-01107-x"
    },
    {
      "title": "HAI Pathogens and Antimicrobial Resistance Report, 2018–2021: Table 5",
      "url": "https://www.cdc.gov/nhsn/hai-report/data-tables-adult/table-5.html"
    },
    {
      "title": "Visualization of Proteus mirabilis within the Matrix of Urease-Induced Bladder Stones during Experimental Urinary Tract Infection",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC127628/"
    },
    {
      "title": "Urinary tract infections in young adult women caused by Staphylococcus saprophyticus",
      "url": "https://pubmed.ncbi.nlm.nih.gov/6644988/"
    },
    {
      "title": "Symptoms & Causes of Bladder Infection in Adults",
      "url": "https://www.niddk.nih.gov/health-information/urologic-diseases/bladder-infection-uti-in-adults/symptoms-causes"
    },
    {
      "title": "IDSA 2016 Clinical Practice Guideline Update for the Management of Candidiasis",
      "url": "https://www.idsociety.org/practice-guideline/candidiasis/"
    },
    {
      "title": "Genetic evidence supporting the fecal-perineal-urethral hypothesis in cystitis caused by Escherichia coli.",
      "url": "https://pubmed.ncbi.nlm.nih.gov/9072556/"
    },
    {
      "title": "Definition & Facts of Kidney Infection (Pyelonephritis)",
      "url": "https://www.niddk.nih.gov/health-information/urologic-diseases/kidney-infection-pyelonephritis/definition-facts?dkrd=www2.niddk.nih.gov"
    },
    {
      "title": "Symptoms & Causes of Kidney Infection (Pyelonephritis)",
      "url": "https://www.niddk.nih.gov/health-information/urologic-diseases/kidney-infection-pyelonephritis/symptoms-causes%20"
    },
    {
      "title": "Uroplakin Ia is the urothelial receptor for uropathogenic Escherichia coli: evidence from in vitro FimH binding.",
      "url": "https://pubmed.ncbi.nlm.nih.gov/11739641/"
    },
    {
      "title": "Damping properties of type 1 fimbriae",
      "url": "https://arxiv.org/abs/1412.2974"
    },
    {
      "title": "Type 1 pilus-mediated bacterial invasion of bladder epithelial cells.",
      "url": "https://pubmed.ncbi.nlm.nih.gov/10856226/"
    },
    {
      "title": "Integrin-Mediated Host Cell Invasion by Type 1–Piliated Uropathogenic Escherichia coli",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC1914067/"
    },
    {
      "title": "Urothelial cultures support intracellular bacterial community formation by uropathogenic Escherichia coli",
      "url": "https://pubmed.ncbi.nlm.nih.gov/19451249/?dopt=Abstract"
    },
    {
      "title": "Detection of Intracellular Bacterial Communities in Human Urinary Tract Infection",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC2140087/"
    },
    {
      "title": "Definition & Facts of Urinary Retention - NIDDK",
      "url": "https://www.niddk.nih.gov/health-information/urologic-diseases/urinary-retention/definition-facts"
    },
    {
      "title": "Insulin receptor signaling engages bladder urothelial defenses that limit urinary tract infection - PubMed",
      "url": "https://pubmed.ncbi.nlm.nih.gov/38517889/"
    },
    {
      "title": "The antimicrobial peptide cathelicidin protects the urinary tract against invasive bacterial infection - PubMed",
      "url": "https://pubmed.ncbi.nlm.nih.gov/16751768/"
    },
    {
      "title": "Interleukin-8 and the neutrophil response to mucosal gram-negative infection - PubMed",
      "url": "https://pubmed.ncbi.nlm.nih.gov/8349817/"
    },
    {
      "title": "Urinary Tract Infection (UTIs) - Forum Health Centre",
      "url": "https://www.forumhealthcentre.nhs.uk/your-health/urinary-tract-infection-utis"
    },
    {
      "title": "Risk factors for recurrent urinary tract infection in young women - PubMed",
      "url": "https://pubmed.ncbi.nlm.nih.gov/10979915/"
    },
    {
      "title": "A controlled trial of intravaginal estriol in postmenopausal women with recurrent urinary tract infections - PubMed",
      "url": "https://pubmed.ncbi.nlm.nih.gov/8350884/"
    },
    {
      "title": "Symptoms & Causes of Urinary Retention - NIDDK",
      "url": "https://www.niddk.nih.gov/health-information/urologic-diseases/urinary-retention/symptoms-causes"
    },
    {
      "title": "Vesicoureteral Reflux (VUR) - NIDDK",
      "url": "https://www.niddk.nih.gov/health-information/urologic-diseases/hydronephrosis-newborns/vesicoureteral-reflux"
    },
    {
      "title": "Bladder Infection (Urinary Tract Infection—UTI) in Adults - NIDDK",
      "url": "https://www.niddk.nih.gov/health-information/urologic-diseases/bladder-infection-uti-in-adults/"
    },
    {
      "title": "Hematuria (Blood in the Urine) - NIDDK",
      "url": "https://www.niddk.nih.gov/health-information/urologic-diseases/hematuria-blood-urine"
    },
    {
      "title": "Strategize Initiatives You Can Incorporate into Your Program - CDC",
      "url": "https://www.cdc.gov/uti/hcp/clinical-guidance/culture-stewardship-strategize.html"
    },
    {
      "title": "Diagnosis of Bladder Infection in Adults - NIDDK",
      "url": "https://www.niddk.nih.gov/health-information/urologic-diseases/bladder-infection-uti-in-adults/diagnosis"
    },
    {
      "title": "Recommendations: Urinary tract infection in under 16s: diagnosis and management",
      "url": "https://www.nice.org.uk/guidance/ng224/chapter/Recommendations"
    },
    {
      "title": "Diagnosis of urinary tract infections: quick reference tools for primary care",
      "url": "https://www.gov.uk/government/publications/urinary-tract-infection-diagnosis/diagnosis-of-urinary-tract-infections-quick-reference-tools-for-primary-care"
    },
    {
      "title": "IDSA: Bacteria in Urine Doesn’t Always Indicate Infection",
      "url": "https://www.idsociety.org/news--publications-new/articles/2019/BACTERIA-IN-URINE-DOESNT-ALWAYS-INDICATE-INFECTION/"
    },
    {
      "title": "Urethritis and Cervicitis - STI Treatment Guidelines",
      "url": "https://www.cdc.gov/std/treatment-guidelines/urethritis-and-cervicitis.htm"
    },
    {
      "title": "Vulvovaginal Candidiasis - STI Treatment Guidelines",
      "url": "https://www.cdc.gov/std/treatment-guidelines/candidiasis.htm"
    },
    {
      "title": "Diseases Characterized by Vulvovaginal Itching, Burning, Irritation, Odor or Discharge",
      "url": "https://www.cdc.gov/std/treatment-guidelines/vaginal-discharge.htm"
    },
    {
      "title": "AUA Guideline for the Diagnosis and Treatment of Interstitial Cystitis/Bladder Pain Syndrome",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC9341322/"
    },
    {
      "title": "Symptoms & Causes of Kidney Stones - NIDDK",
      "url": "https://www.niddk.nih.gov/health-information/urologic-diseases/kidney-stones/symptoms-causes"
    },
    {
      "title": "IDSA 2019 Clinical Practice Guideline Update for the Management of Asymptomatic Bacteriuria",
      "url": "https://www.idsociety.org/practice-guideline/asymptomatic-bacteriuria/"
    },
    {
      "title": "Recommendation: Asymptomatic Bacteriuria in Adults: Screening",
      "url": "https://www.uspreventiveservicestaskforce.org/uspstf/index.php/recommendation/asymptomatic-bacteriuria-in-adults-screening"
    },
    {
      "title": "Urinary Tract Infections in Pregnant Individuals",
      "url": "https://www.acog.org/clinical/clinical-guidance/clinical-consensus/articles/2023/08/urinary-tract-infections-in-pregnant-individuals"
    },
    {
      "title": "Urothelial cells may indicate underlying bacteriuria in pregnancy at term: a comparative study",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC5723065/"
    },
    {
      "title": "Recommendations | Urinary tract infection (lower): antimicrobial prescribing",
      "url": "https://www.nice.org.uk/guidance/ng109/chapter/Recommendations"
    },
    {
      "title": "Symptoms & Causes of Bladder Infection in Children - NIDDK",
      "url": "https://www.niddk.nih.gov/%20health-information/urologic-diseases/urinary-tract-infections-in-children/symptoms-causes"
    },
    {
      "title": "Optimizing management of urinary tract infections in children: A need for improved stewardship",
      "url": "https://cps.ca/en/documents/position/management-urinary-tract-infections"
    },
    {
      "title": "Urinary tract infection in under 16s: diagnosis and management",
      "url": "https://www.nice.org.uk/guidance/ng224/resources/urinary-tract-infection-in-under-16s-diagnosis-and-management-pdf-66143835667141"
    },
    {
      "title": "Summary of the evidence | Urinary tract infection (lower): antimicrobial prescribing | Guidance | NICE",
      "url": "https://www.nice.org.uk/guidance/ng109/chapter/summary-of-the-evidence"
    },
    {
      "title": "The Guideline - EAU Guidelines on Urological Infections - Uroweb",
      "url": "https://uroweb.org/guidelines/urological-infections/chapter/the-guideline"
    },
    {
      "title": "Urinary tract infections in solid organ transplant recipients: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice",
      "url": "https://pubmed.ncbi.nlm.nih.gov/30793386/"
    },
    {
      "title": "IDSA 2025 Guideline Update on Complicated Urinary Tract Infections",
      "url": "https://www.idsociety.org/practice-guideline/complicated-urinary-tract-infections/"
    },
    {
      "title": "V. Background",
      "url": "https://www.cdc.gov/infection-control/hcp/cauti/background.html"
    },
    {
      "title": "Summary of Recommendations",
      "url": "https://www.cdc.gov/infection-control/hcp/cauti/summary-of-recommendations.html"
    },
    {
      "title": "Urinary Tract Infection: January 2026, Device-associated Module",
      "url": "https://www.cdc.gov/nhsn/pdfs/pscmanual/7psccauticurrent.pdf?sortBy=newest&topics=18"
    },
    {
      "title": "Effect of 5-Day Nitrofurantoin vs Single-Dose Fosfomycin on Clinical Resolution of Uncomplicated Lower Urinary Tract Infection in Women: A Randomized Clinical Trial",
      "url": "https://pubmed.ncbi.nlm.nih.gov/29710295/"
    },
    {
      "title": "Nitrofurantoin: reminder of the risks of pulmonary and hepatic adverse drug reactions",
      "url": "https://www.gov.uk/drug-safety-update/nitrofurantoin-reminder-of-the-risks-of-pulmonary-and-hepatic-adverse-drug-reactions"
    },
    {
      "title": "Summary of the evidence | Pyelonephritis (acute): antimicrobial prescribing | Guidance | NICE",
      "url": "https://www.nice.org.uk/guidance/NG111/chapter/summary-of-the-evidence"
    },
    {
      "title": "Recommendations | Pyelonephritis (acute): antimicrobial prescribing | Guidance | NICE",
      "url": "https://www.nice.org.uk/guidance/ng111/chapter/recommendations"
    },
    {
      "title": "Clinical Practice Guidelines by Infectious Diseases Society of America (IDSA): 2025 Guidelines on Management and Treatment of Complicated Urinary Tract Infections—Duration of Antibiotics for Complicated UTI",
      "url": "https://pubmed.ncbi.nlm.nih.gov/41419448/"
    },
    {
      "title": "Recommendations | Urinary tract infection (recurrent): antimicrobial prescribing | Guidance | NICE",
      "url": "https://www.nice.org.uk/guidance/ng112/chapter/Recommendations"
    },
    {
      "title": "Topical Estrogens Prevent UTI in Postmenopausal Women",
      "url": "https://clinician.nejm.org/topical-estrogens-prevent-uti-postmenopausal-women-JW199309240000004"
    },
    {
      "title": "Summary of the evidence | Urinary tract infection (recurrent): antimicrobial prescribing | Guidance | NICE",
      "url": "https://www.nice.org.uk/guidance/ng112/chapter/Summary-of-the-evidence"
    },
    {
      "title": "Cranberries for preventing urinary tract infections | Cochrane",
      "url": "https://www.cochrane.org/evidence/CD001321_cranberries-preventing-urinary-tract-infections"
    },
    {
      "title": "Infections and Sepsis",
      "url": "https://health.nih.gov/health-topics-a-z/infection-and-sepsis"
    },
    {
      "title": "Recent clinical overview of renal and perirenal abscesses in 56 consecutive cases",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC2686968/"
    },
    {
      "title": "Renal and perinephric abscesses in West China Hospital: 10-year retrospective-descriptive study",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC4707163/"
    },
    {
      "title": "Prognosis of Extended-Spectrum-Beta-Lactamase-Producing Agents in Emphysematous Pyelonephritis-Results from a Large, Multicenter Series",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC9786570/"
    },
    {
      "title": "Long-term consequences of urinary tract infection in childhood: an electronic population-based cohort study in Welsh primary and secondary care",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC11147460/"
    },
    {
      "title": "IDSA 2026 Guidance on the Treatment of Antimicrobial Resistant Gram-Negative Infections",
      "url": "https://www.idsociety.org/practice-guideline/amr-guidance?n=%40"
    },
    {
      "title": "Urothelial cultures support intracellular bacterial community formation by uropathogenic Escherichia coli",
      "url": "https://pubmed.ncbi.nlm.nih.gov/19451249/"
    },
    {
      "title": "IDSA releases new guidelines for management and treatment of complicated urinary tract infections",
      "url": "https://www.idsociety.org/news--publications-new/articles/2025/idsa-releases-new-guidelines-for-management-and-treatment-of-complicated-urinary-tract-infections/"
    }
  ],
  "license": "https://creativecommons.org/licenses/by/4.0/"
}